DK3744835T3 - Dna modificerende fusionsproteiner og metoder til anvendelse deraf - Google Patents

Dna modificerende fusionsproteiner og metoder til anvendelse deraf Download PDF

Info

Publication number
DK3744835T3
DK3744835T3 DK20183740.8T DK20183740T DK3744835T3 DK 3744835 T3 DK3744835 T3 DK 3744835T3 DK 20183740 T DK20183740 T DK 20183740T DK 3744835 T3 DK3744835 T3 DK 3744835T3
Authority
DK
Denmark
Prior art keywords
methods
fusion proteins
dna modifying
modifying fusion
dna
Prior art date
Application number
DK20183740.8T
Other languages
English (en)
Other versions
DK3744835T5 (da
Inventor
Keith J Joung
Morgan Maeder
James Angstman
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of DK3744835T3 publication Critical patent/DK3744835T3/da
Application granted granted Critical
Publication of DK3744835T5 publication Critical patent/DK3744835T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK20183740.8T 2012-05-29 2013-05-29 Dna modificerende fusionsproteiner og metoder til anvendelse deraf DK3744835T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652711P 2012-05-29 2012-05-29
US13/838,520 US9890364B2 (en) 2012-05-29 2013-03-15 TAL-Tet1 fusion proteins and methods of use thereof
EP13797024.0A EP2879693B1 (en) 2012-05-29 2013-05-29 Dna modifying fusion proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
DK3744835T3 true DK3744835T3 (da) 2024-05-06
DK3744835T5 DK3744835T5 (da) 2024-08-26

Family

ID=49670524

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20183740.8T DK3744835T5 (da) 2012-05-29 2013-05-29 Dna modificerende fusionsproteiner og metoder til anvendelse deraf

Country Status (6)

Country Link
US (4) US9890364B2 (da)
EP (4) EP3744835B1 (da)
DK (1) DK3744835T5 (da)
ES (1) ES2979326T3 (da)
PT (1) PT3744835T (da)
WO (1) WO2013181228A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841710C (en) 2011-07-15 2021-03-16 The General Hospital Corporation Methods of transcription activator like effector assembly
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
US9828582B2 (en) * 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3540061A1 (en) 2014-04-02 2019-09-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
WO2015191911A2 (en) * 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP4019975A1 (en) 2015-04-24 2022-06-29 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066796A2 (en) * 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
WO2017189542A1 (en) * 2016-04-26 2017-11-02 University Of Georgia Research Foundation, Inc. Plants having reduced methylation of cytosine nucleotides and methods of use
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
CN109715194B (zh) 2016-08-03 2024-06-11 南佛罗里达大学 用于治疗神经障碍的颤蛋白组合物
AU2017327384B2 (en) 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
KR102662249B1 (ko) 2016-10-14 2024-05-03 더 제너럴 하스피탈 코포레이션 후성적으로 조절되는 부위-특이적 뉴클레아제
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
AU2018213044B2 (en) * 2017-01-26 2024-08-01 The Regents Of The University Of California Targeted gene demethylation in plants
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
CA3089562A1 (en) 2018-01-30 2019-08-08 University Of Massachusetts Methods of treating a wound using epigenetic regulation
IL277234B2 (en) 2018-03-14 2026-03-01 Editas Medicine Inc Systems and methods for treating hemoglobin diseases
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
US12692542B2 (en) * 2019-05-29 2026-07-28 EpiMedTechGlobal (EMTG) EpiAging ; novel ecosystem for managing healthy aging
CN111700034B (zh) * 2020-05-22 2021-12-14 中国人民解放军空军军医大学 一种基于中枢神经系统髓鞘功能改变的精神分裂症动物模型的构建方法和应用
US20250388894A1 (en) * 2022-09-30 2025-12-25 Illumina, Inc. Methods of using cpg binding proteins in mapping modified cytosine nucleotides

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6900306B2 (en) 2001-08-01 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of CoREST expression
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993019202A2 (en) 1992-03-10 1993-09-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Exchangeable template reaction
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
KR960702518A (ko) 1993-05-17 1996-04-27 린다 에스, 스티븐슨 Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids)
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9618544D0 (en) 1996-09-05 1996-10-16 Brax Genomics Ltd Characterising DNA
DE19812103A1 (de) 1998-03-19 1999-09-23 Bernauer Annette Verfahren zur Synthese von Nucleinsäuremolekülen
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
DE19925862A1 (de) 1999-06-07 2000-12-14 Diavir Gmbh Verfahren zur Synthese von DNA-Fragmenten
US20020164575A1 (en) 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification
WO2001053480A1 (en) 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
AU2001257331A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
JP2003531616A (ja) 2000-04-28 2003-10-28 サンガモ バイオサイエンシーズ， インコーポレイテッド 細胞性クロマチンに外因性分子を結合させるための方法
EP1276859B1 (en) 2000-04-28 2007-02-07 Sangamo Biosciences Inc. Targeted modification of chromatin structure
US7029847B2 (en) 2000-05-16 2006-04-18 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
JP2002262870A (ja) 2000-11-09 2002-09-17 Nara Institute Of Science & Technology 固相において二本鎖ｄｎａ分子を順次連結する方法およびその装置
US7947469B2 (en) 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2003304086A1 (en) 2002-10-23 2004-11-26 Massachussetts Institute Of Technlogy Context sensitive parallel optimization of zinc finger dna binding domains
US7741086B2 (en) 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ＪｍｊＣドメインを含むタンパク質デメチラーゼ
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
EP2027262B1 (en) 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variant foki cleavage half-domains
AU2008304459B2 (en) 2007-09-28 2013-10-03 Two Blades Foundation Bs3 resistance gene and methods of use
EP2297182A4 (en) 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
BRPI0921909A2 (pt) 2008-11-10 2017-06-13 Two Blades Found métodos para fabricar um promotor indutível por patógeno, e um gene r, para intensificar a resistência de uma planta, e para identificar uma caixa upa, promotor indutível por patógeno, cassete de expressão, molécula de ácido nucléico, planta transformada, semente da planta transformada, célula hospedeira.
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
CN102612565B (zh) 2009-08-11 2016-04-06 桑格摩生物科学股份有限公司 靶向修饰的纯合生物体
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
JP6137596B2 (ja) 2010-02-08 2017-05-31 サンガモ セラピューティクス， インコーポレイテッド 遺伝子操作された切断ハーフドメイン
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
CA2841710C (en) 2011-07-15 2021-03-16 The General Hospital Corporation Methods of transcription activator like effector assembly
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
AU2017302551B2 (en) 2016-07-26 2023-04-27 The General Hospital Corporation Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
WO2019040650A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
US20230036273A1 (en) 2019-11-27 2023-02-02 The General Hospital Corporation System and method for activating gene expression
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
EP4093864A4 (en) 2020-01-24 2024-04-10 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants

Also Published As

Publication number Publication date
US9890364B2 (en) 2018-02-13
EP2879693A1 (en) 2015-06-10
EP4368249A2 (en) 2024-05-15
EP2879693B1 (en) 2020-07-08
EP3747999B1 (en) 2021-09-15
ES2979326T3 (es) 2024-09-25
EP2879693A4 (en) 2016-04-13
US20130323220A1 (en) 2013-12-05
EP3747999A1 (en) 2020-12-09
US20210155907A1 (en) 2021-05-27
EP4368249A3 (en) 2024-07-24
US10894950B2 (en) 2021-01-19
US20180187168A1 (en) 2018-07-05
EP3744835B1 (en) 2024-01-31
US12152254B2 (en) 2024-11-26
EP3744835A1 (en) 2020-12-02
US20250115884A1 (en) 2025-04-10
WO2013181228A1 (en) 2013-12-05
DK3744835T5 (da) 2024-08-26
PT3744835T (pt) 2024-05-31

Similar Documents

Publication Publication Date Title
DK3744835T5 (da) Dna modificerende fusionsproteiner og metoder til anvendelse deraf
DK3489254T3 (da) Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
DK3725807T3 (da) Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
CL2014003605A1 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
DK3578659T3 (da) Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
DK3058092T3 (da) Fremgangsmåder og præparater til fremstilling af nukleinsyrebiblioteker
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2852680T3 (da) Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
DK2859017T3 (da) Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2912174T3 (da) Fremgangsmåde og materialer til isolering af nukleinsyrematerialer
IL230209B (en) Serpin fusion polypeptides and methods of use thereof
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
CO7020851A2 (es) Proteínas y péptidos modificados
ZA201503583B (en) Dna antibody constructs and method of using same
DK3434775T3 (da) Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf
DK3604339T3 (da) Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
DK2812356T3 (da) CDIM-bindende proteiner og anvendelser deraf
SI2968461T1 (sl) Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse